The American Journal of Managed Care

Clinical Impact of Oral SERDs

Dr Lu and Dr Vidula review the clinical impact of oral selective estrogen receptor degraders (SERDs) on disease progression and response rates in patients with ER+/HER2- metastatic breast cancer and ...
The American Journal of Managed Care

Differences Between SERDs and Other Therapies

Dr Vidula and Dr Lu describe how selective estrogen receptor degraders (SERDs) differ in their mechanism of action from other therapies for ER+/HER2– metastatic breast cancer and how newer SERDs ...
Cure Today

ESMO Breast Cancer 2026: 3 Key Takeaways

Dr. Erica Mayer of Dana-Farber highlights new data on chemotherapy-free HER2+ treatment, ctDNA monitoring and oral SERDs at ESMO Breast 2026. In the wake of the 2026 ESMO Breast Cancer conference, ...
Yahoo Finance

SERD Market is Predicted to Exhibit Remarkable Growth Owing to the Usage of Faslodex in Combination, Strong Performance of ORSERDU, and Speedy Progress of Other Oral SERDs ...

DelveInsight's SERD Market Insights report includes a comprehensive understanding of current prescribing patterns and in patients with or without emerging oral SERDs in both early and advanced forms ...